Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
This combination can enhance overall metabolic support during fat loss phases
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
2001, AOD-9604 lost most of this fat-metabolism effect in mice that were genetically missing the beta-3 adrenergic receptor, suggesting that pathway carries part of the signal
May your peptide choices stay informed, your results stay visible, and your protocols stay optimized
Always satisfied with my products
Some compounded formulations include additional ingredients designed to enhance stability, absorption, or complementary effects
US$ 22.38
US$ 22.36
US$ 27.09
US$ 24.37
